STEMON Inc. participated in SPOGA HORSE 2026, held February 7–9 at Koelnmesse in Cologne, Germany, where the company showcased its advanced exosome-based technology for veterinary wound care.During the exhibition, STEMON highlighted STMD-02 (Repropet®), an innovative wound care solution for animals designed to support enhanced healing and tissue regeneration. Clinical case examples presented at the booth demonstrated effective control of inflammation, stabilization of the wound environment, and improved tissue regeneration, underscoring the growing potential of exosome-based therapy in veterinary applications.The event provided a valuable opportunity to connect with professionals across equine care, veterinary medicine, animal health, and biotechnology. Building on the meaningful discussions and industry interest received at SPOGA HORSE, STEMON looks forward to expanding global collaborations and continuing to advance regenerative exosome solutions for animal treatment.

STEMON Inc. showcased its innovative exosome-based digital bio-platform technologies at COSME WEEK TOKYO 2026,engaging with global beauty professionals through insightful and inspiring discussions. During the exhibition, STEMON introduced its latest innovations, including the Plant Color Exosome (VitB12) and Ginseng PDRN Exosomewhich quickly became some of the most discussed highlights at our booth. The strong interest and active engagement around these plant-derived,exosome-based solutions reaffirmed our vision for the future of beauty and skincare. Notably, STEMON recorded one of the highest QR code engagement rates across the entire exhibition and was selected as one of the Top 10 Innovative Ingredientsamong all participating companies, underscoring the industry’s recognition of our technological leadership. Building on the meaningful connections and productive exchanges throughout the event, STEMON looks forward to exploring future collaborationopportunities and further strengthening its global leadership in digital bio-innovation.

​STEMON Inc. participated in VIV MEA 2025, held in Abu Dhabi in November 2025, where the company showcased its premium medical device–grade exosome technology for advanced veterinary wound care. At the exhibition, STEMON unveiled Repropet®, a next-generation wound care solution for pets powered by Reprosome®, a high-purity, exosome platform produced through digital reprogramming. The innovative product drew significant interest as a regenerative, science-driven approach to veterinary wound management. As a bio-platform company developing therapeutics for intractable diseases, medical devices, and research-grade exosomes, STEMON will continue expanding global partnerships and advancing digital exosome innovation through its proprietary automated induction system, UltraRepro®.

STEMON Inc. showcased its innovative exosome-based digital bio-platform technologies at COSMOPROF HONG KONG 2025, engaging with global visitors through insightful and inspiring discussions. During the exhibition, STEMON presented UltraRepro®, its automated exosome induction platform, and DDDS®, its digital exosome drug-loading automation system, setting new standards in digitalized biotechnology and gaining strong interest across the cosmetics, medical device, and advanced therapeutic sectors. Building on the meaningful connections made throughout the event, STEMON looks forward to exploring future collaboration opportunities and further strengthening its global leadership in digital bio-innovation.

STEMON Inc. participated in CIIE 2025, held from November 5–10 in Shanghai, where the company showcased its innovative exosome-based technologies. During the exhibition, STEMON presented UltraRepro®, its automated exosome induction system, and DDDS®, a digital exosome drug-loading platform, two breakthrough technologies that bridge beauty, biotechnology, and digital innovation, drawing significant interest from industry experts and visitors. Through its presence at CIIE, STEMON highlighted how premium exosome solutions are shaping the future of beauty and healthcare, while strengthening its global technological leadership.

STEMON Showcases ‘DDDS Platform’ and Exosome Technology Loaded with Hyaluronic Acid and PLLA at Cosmetics 360 Paris STEMON showcased its next-generation exosome innovations at the Cosmetics 360 exhibition held in Paris, France, presenting functional plant-derived exosomes loaded with hyaluronic acid (HA) and PLLA, along with the next-generation “Sterile Exosome Bio-Cellulose 5th Generation Mask Pack.”During the exhibition, STEMON drew significant attention by holding business meetings with global beauty leaders such as L’Oréal, LVMH, Proya, and Chanel.In particular, its new product, “BONSOIN Mask Pack,” received high praise as a “next-generation premium mask pack combining innovation and market competitiveness.”Furthermore, STEMON was nominated as a finalist in the Manufacturing Process category of the Cosmetic 360 Awards, a recognition of its technological excellence and innovation in exosome production processes on a global scale. Building on this achievement, STEMON aims to advance toward becoming a global leader in bio-cosmetics under its vision of “Digital beyond Biology.”

Showcases Exosome-Based Veterinary Medical Device “ReproPet”STEMON took part in Pet Fair Asia in Shanghai, one of the world’s largest exhibitions for companion animals, where it showcased its exosome-based veterinary medical device “ReproPet.”ReproPet applies exosome technology to support regenerative treatment and health recovery for pets, offering an advanced solution in the veterinary field. The product drew significant interest from industry experts and buyers during the exhibition. STEMON stated that it will leverage this event to further raise awareness of its technological competitiveness in animal healthcare and accelerate its expansion into global markets.

Launches Two New Exosome-Based Products with Filler Ingredients, Attracting Strong InterestSTEMON participated in the beauty exhibition In-Cosmetics Korea, unveiling two innovative new products that incorporate filler ingredients into exosomes.The launch drew significant attention from visitors and industry professionals alike. The newly introduced products stand out as advanced solutions for skin regeneration and improved elasticity, offering a scientific approach that differentiates them from conventional skincare. The exhibition generated active discussions with buyers and experts, who responded positively to the company’s technology. STEMON announced that it will leverage this exhibition as a stepping stone to strengthen its presence in both domestic and international markets, while further solidifying its technological competitiveness in the global beauty industry.